Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for November 7, 2024 at 2:00 p.m. PT / 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics…
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
RMAT Designation Follows Positive Proof-of-Concept Data from the ALLO-316 TRAVERSE Trial in Adult Patients with Advanced or Metastatic CD70 Positive Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor…
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
The CD19/CD70 Dual CAR is Specifically Designed to Address Both the B-cell and T-cell Dysfunction Implicated in Autoimmune Diseases ALLO-329, is an Investigational Product Built on a New Gene Editing…
- Go to the previous page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- 16
- Go to the next page